Upcoming EHA 2024 Presentations from Omeros Corporation

Omeros Corporation, a biopharmaceutical firm listed on Nasdaq, has announced that the interim data from its ongoing Phase 2 clinical trial of OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) has been chosen for a podium presentation at the 2024 European Hematology Association (EHA) Hybrid Congress. The event will take place from June 13 to 16 in Madrid, Spain. OMS906 is an experimental inhibitor of MASP-3, which is a critical component of the alternative pathway of the complement system.

Two additional presentations related to OMS906 are planned for the congress, with the abstracts for all presentations set to be published on May 14, 2024, and made available on the EHA website. The presentations will cover various aspects of OMS906, including its impact on hematologic parameters in PNH patients and its clinical pharmacology.

OMS906 is a humanized monoclonal antibody that targets MASP-3, which is believed to be a key activator of the complement system's alternative pathway. The complement system is integral to inflammation and is activated in response to tissue damage or microbial infection. MASP-3 is considered a primary target in this pathway due to its unique characteristics, such as its low native circulating level and its role in the conversion of pro-complement factor D to complement factor D. Inhibition of MASP-3 is thought to have potential benefits over other alternative pathway inhibitors, as it does not affect the lytic arm of the classical pathway, which is crucial for combating infections.

OMS906 is also distinguished from other components of the alternative pathway, as it is not believed to be an acute phase reactant. This could offer significant advantages to MASP-3 inhibitors like OMS906 in terms of their therapeutic effects. The drug is being studied for its potential to prevent or treat a wide range of diseases, including PNH, hemolytic uremic syndrome (HUS), traumatic brain injury, arthritis, and other immune-related disorders.

Omeros is dedicated to the discovery, development, and commercialization of therapeutics for a variety of indications, with a focus on immunologic disorders, complement-mediated diseases, cancers, and disorders related to addiction and compulsion. The company's lead MASP-2 inhibitor, narsoplimab, is currently under review by the FDA for the treatment of a condition associated with hematopoietic stem cell transplants. Additionally, Omeros is developing other MASP inhibitors and is advancing programs in immuno-oncology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!